February 2, 2021

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.